Advanced Gastric Carcinoma Clinical Trial
Official title:
Safety and Feasibility of Double-Stapling End-to-End Gastroduodenostomy Billroth-I Anastomosis in Laparoscopy-Assisted Surgery for Locally Advanced Distal Gastric Cancers: A Prospective Cohort Study
NCT number | NCT05545293 |
Other study ID # | YZhou |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | September 14, 2022 |
Est. completion date | December 31, 2023 |
The purpose of this study is to explore the clinical application value of Double-Stapling End-to-End Gastroduodenostomy Billroth-I Anastomosis in Laparoscopy-Assisted Surgery for Locally Advanced Distal Gastric Cancers.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | December 31, 2023 |
Est. primary completion date | August 1, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility | Inclusion Criteria: - Age from 18 to years (including 18 and 85years old) - Pathological diagnosis of primary focus is gastric adenocarcinoma made by endoscopic biopsy (papillary, tubular, mucinous, signet ring cell, poorly differentiated) - cT1-4a, N+/-, M0 at preoperative evaluation - No peritoneal metastasis or other distant metastases of gastric carcinoma (affirmed by laparoscopic surgery and related imaging examinations) - Expected curative resection through laparoscopic distal gastrectomy with D2 lymphadenectomy (include multiple primary lower gastric adenocarcinoma) - Performance status of 0 or 1 on Eastern Cooperative Oncology Group scale (ECOG) - Preoperative American Society of Anesthesiology score (ASA) class?, ? or ? - Major organs are functioning normally: blood routine test (No blood transfusions in the last 14 days): HB=90g/L, ANC=1.5×109/L, PLT=80×109/L blood biochemical examination: BIL<1.5× upper limit of normal (ULN), ALT and AST<2.5×ULN, Crea=1×ULN. - The subject is willing to participate in this clinical trail Exclusion Criteria: - History of previous upper abdominal surgery (include ESD/EMR, except laparoscopic cholecystectomy) - History of acute pancreatitis - Regional fusion of enlarged lymph nodes by preoperative imaging (maximum diameter >3cm) - History of other malignant disease within past five years - History of unstable angina, myocardial infarction, cerebral infraction, or cerebral hemorrhage within past six months - History of continuous systematic corticosteroids therapy within past one month - Requirement of simultaneous surgery for other disease - Emergency surgery due to complication (bleeding, or perforation) caused by gastric cancer - FEV1<50% of predicted values by pulmonary function test - Women during pregnancy or breast-feeding - Severe mental disorder - Participating in other clinical studies simultaneously - Refusing to sign the informed consent for the study - Peritoneal implant or other distant metastases by intraoperative exploration - Unresectable due to tumor reasons by intraoperative exploration - Distal gastric cancer surgery cannot be performed after intraoperative exploration - Duodenal bulb has been invaded by tumor or gastroduodenostomy cannot be performed due to additional surgical resection cause by positive intraoperative frozen margin |
Country | Name | City | State |
---|---|---|---|
China | West China Hospital, Sichuan University | Chengdu | Sichuan |
Lead Sponsor | Collaborator |
---|---|
West China Hospital |
China,
Cai Z, Zhou Y, Wang C, Yin Y, Yin Y, Shen C, Yin X, Chen Z, Zhang B. Optimal reconstruction methods after distal gastrectomy for gastric cancer: A systematic review and network meta-analysis. Medicine (Baltimore). 2018 May;97(20):e10823. doi: 10.1097/MD.0 — View Citation
Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021 Jan;24(1):1-21. doi: 10.1007/s10120-020-01042-y. Epub 2020 Feb 14. — View Citation
Jin HE, Kim MS, Lee CM, Park JH, Choi CI, Lee HH, Min JS, Jee YS, Oh J, Chae H, Choi SI, Lee YT, Kim JH, Huang H, Park S. Meta-analysis and systematic review on laparoscopic-assisted distal gastrectomy (LADG) and totally laparoscopic distal gastrectomy (T — View Citation
Kanaya S, Gomi T, Momoi H, Tamaki N, Isobe H, Katayama T, Wada Y, Ohtoshi M. Delta-shaped anastomosis in totally laparoscopic Billroth I gastrectomy: new technique of intraabdominal gastroduodenostomy. J Am Coll Surg. 2002 Aug;195(2):284-7. — View Citation
Kuwabara Y, Shinoda N, Sato A, Kimura M, Ishiguro H, Sugiura H, Tanaka T, Ando T, Fujii Y, Fujii Y. Billroth I gastroduodenostomy using a hemi-double stapling technique. J Am Coll Surg. 2004 Apr;198(4):670-2. — View Citation
Lin M, Zheng CH, Huang CM, Li P, Xie JW, Wang JB, Lin JX, Lu J, Chen QY, Cao LL, Tu RH. Totally laparoscopic versus laparoscopy-assisted Billroth-I anastomosis for gastric cancer: a case-control and case-matched study. Surg Endosc. 2016 Dec;30(12):5245-52 — View Citation
Nishizaki D, Ganeko R, Hoshino N, Hida K, Obama K, Furukawa TA, Sakai Y, Watanabe N. Roux-en-Y versus Billroth-I reconstruction after distal gastrectomy for gastric cancer. Cochrane Database Syst Rev. 2021 Sep 15;9:CD012998. doi: 10.1002/14651858.CD012998 — View Citation
Oka M, Maeda Y, Ueno T, Iizuka N, Abe T, Yamamoto K, Ogura Y, Masaki Y, Suzuki T. A hemi-double stapling method to create the Billroth-I anastomosis using a detachable device. J Am Coll Surg. 1995 Oct;181(4):366-8. — View Citation
Park SH, Kang MJ, Yun EH, Jung KW. Epidemiology of Gastric Cancer in Korea: Trends in Incidence and Survival Based on Korea Central Cancer Registry Data (1999-2019). J Gastric Cancer. 2022 Jul;22(3):160-168. doi: 10.5230/jgc.2022.22.e21. Review. — View Citation
Yang HK, Lee HJ, Ahn HS, Yoo MW, Lee IK, Lee KU. Safety of modified double-stapling end-to-end gastroduodenostomy in distal subtotal gastrectomy. J Surg Oncol. 2007 Dec 1;96(7):624-9. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Anastomotic complications | The anastomotic complications are defined as the event observed within 30 days after surgery, including anastomotic stenosis, anastomotic bleeding, and anastomotic leakage. | up to 1-30 Days after surgery | |
Primary | Intraoperative situation | Operation time, anastomotic reconstruction time, operative blood loss, completed proportion of laparoscopic surgery, positive rate of Intraoperative frozen margin pathology, anastomotic tension, the distance between proximal and distal of resection margin, the incidence of complication in surgery are used to access the intraoperative situation. | on the day of surgery | |
Primary | Postoperative nutritional status and quality of life | The variation of weight, cholesterol and albumin on postoperative 30 days are used to access the postoperative nutritional status and quality of life. | up to 1-30 Days after surgery | |
Secondary | Length of hospital stay | The time between end of surgery and written discharge ticket | up to 1-30 Days after surgery | |
Secondary | Cost of hospitalization | The fees paid during the course of this hospitalization | up to 1-30 Days after hospital admission | |
Secondary | Other postoperative complications | Other postoperative complications are defined as events other than anastomotic complications occurring within 30 days after surgery. | up to 1-30 Days after surgery | |
Secondary | Postoperative intestinal function recovery time | The time between end of surgery and first bowel movement | up to 1-6 Days after surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04808791 -
iTTo for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
|
Phase 2 | |
Recruiting |
NCT05620732 -
Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T
|
N/A | |
Recruiting |
NCT05221775 -
Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients
|
Phase 1 | |
Completed |
NCT05334849 -
Prospectively Predict the Immunotherapy Response of Gastric Cancer Based on Circulating Exosomal LncRNA-GC1 Biopsy
|
||
Not yet recruiting |
NCT05313906 -
RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer
|
Phase 2 | |
Completed |
NCT00192088 -
A Study of Pemetrexed Plus Oxaliplatin as First Line Therapy in Advanced Gastric Carcinoma
|
Phase 2 | |
Terminated |
NCT04718402 -
A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric Carcinoma
|
Phase 1 | |
Active, not recruiting |
NCT01534546 -
Phase III Study to Compare Perioperative Chemotherapy of Oxaliplatin Combined With S-1(SOX) Versus SOX or Oxaliplatin With Capecitabine (XELOX) as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma With D2 Dissection
|
Phase 3 | |
Recruiting |
NCT04739202 -
Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)
|
Phase 2 | |
Not yet recruiting |
NCT05270824 -
Study Evaluating Neoadjuvant Immunotherapy Increasing CD8+ Cell Infiltration in Advance Gastric Adenocarcinoma
|
Phase 3 | |
Completed |
NCT05997524 -
Clinical Efficacy of Trastuzumab in Combination With Capecitabine and Oxaliplatin for the Treatment of HER2-positive Advanced Gastric Cancer.
|
Phase 2 | |
Recruiting |
NCT06264921 -
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05805956 -
IMM2902 in Patients With Advanced Solid Tumors Expressing HER2
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT02163291 -
Study on Neoadjuvant Chemotherapy for Advanced Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT04704661 -
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
|
Phase 1 | |
Recruiting |
NCT06028737 -
Total Neoadjuvant Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04491942 -
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
|
Phase 1 | |
Recruiting |
NCT05969860 -
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04535401 -
Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines
|
Phase 1 | |
Recruiting |
NCT05226169 -
Efficacy and Safety oF FErric CarboxymalTose in Patients With Advanced Gastric Cancer(EFFECT-AGC)
|
Phase 3 |